Navigation Links
New approach to treating human brain cancer could lead to improved outcomes
Date:9/25/2013

LA JOLLA, Calif., September 25 2013 A new experimental approach to treating a type of brain cancer called medulloblastoma has been developed by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham). The method targets cancer stem cellsthe cells that are critical for maintaining tumor growthand halts their ability to proliferate by inhibiting enzymes that are essential for tumor progression. The process destroys the ability of the cancer cells to grow and divide, paving the way for a new type of treatment for patients with this disease.

The research team, led by Robert Wechsler-Reya, Ph.D., professor in Sanford-Burnham's NCI-Designated Cancer Center and director of the Tumor Initiation and Maintenance Program, discovered that the medulloblastoma cancer cells responsible for tumor growth and progression (called cancer stem cells or tumor-propagating cellsTPCs) divide more quickly than normal cells. Correspondingly, they have higher levels of certain enzymes that regulate the cell cycle (Aurora and Polo-like kinases). By using small-molecule inhibitors to stop the action of these enzymes, the researchers were able to block the growth of tumor cells from mice as well as humans. The research findings are described in an online paper published September 25 by Cancer Research.

"One tumor can have many different types of cells in it, and they can grow at different rates. By targeting fast-growing TPCs with cell-cycle inhibitors, we have developed a new route to assault medulloblastoma. In this study, we have shown that cell-cycle inhibitors essentially block medulloblastoma tumor progression by halting TPC expansion, and have opened the window to preventing cancer recurrence," said Wechsler-Reya.

For their research, the scientists tested the effectiveness of cell-cycle inhibitors in a specific type of brain cancer called Sonic Hedgehog (SHH)-associated medulloblastoma. These cancers have mutations in components o
'/>"/>

Contact: Susan Gammon, Ph.D.
sgammon@sanfordburnham.org
310-610-3808
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. A new approach to early diagnosis of influenza
2. Novel approach to gene regulation can activate multiple genes simultaneously
3. Mechanism offers promising new approach for harnessing the immune system to fight cancer
4. Study highlights possible new approach to prostate cancer treatment
5. Notre Dame researchers develop system that uses a big data approach to personalized healthcare
6. New approach to protecting prion protein from altering shape
7. New data support community-wide approach to addressing child obesity
8. A Future-Proof Approach to Intelligent Buildings
9. New chemical approach to treat Alzheimers
10. Agencies should use common approach to evaluate risks pesticides pose to endangered species
11. Novel therapeutic approaches to cure chronic HBV infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... , April 2, 2015 ... touch fingerprint sensor FPC1025 from the distributor World Peace ... commence during Q2 2015 although the major part of ... sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... of autism spectrum disorders (ASD) is impairments in ... face difficulty understanding, interacting and relating with others. ... receive more intensive therapy to combat these impairments, ... "It,s important for children with ...
... Precourt Institute for Energy (PIE) and TomKat Center for ... more than $2.2 million for promising new research in ... is to help jumpstart new projects with the potential ... Lynn Orr, professor of energy resources engineering. "These ...
... a key regulator that controls the speed of development in ... this regulator, animals sped up their rate of development and ... of A research team, led by molecular geneticist Kirst King-Jones, ... DHR4: The protein acted as a sentinel to either allow ...
Cached Biology News:Children with autism benefit from early, intensive therapy 2Stanford Precourt Institute and TomKat Center award energy research grants 2Stanford Precourt Institute and TomKat Center award energy research grants 3Stanford Precourt Institute and TomKat Center award energy research grants 4Stanford Precourt Institute and TomKat Center award energy research grants 5
(Date:5/5/2015)... , May 5, 2015 ImmunoCellular ... Andrew Gengos , President and Chief Executive ... 7, 2015. DATE:  Thursday, May 7, 2015     ... http://VirtualInvestorConferences.com > click the red "register/ ... a live, interactive online event where investors are ...
(Date:5/5/2015)... and WASHINGTON, D.C., USA (PRWEB) May 05, 2015 ... U.S. export regulations covering a wide range of key ... say are hampering global competitiveness of U.S. industry. To ... a webinar on 12 May on the ... which governs the commodities covered by International Traffic in ...
(Date:5/5/2015)... 05, 2015 Research and Markets ... the "Clinical Laboratory, Molecular Diagnostics and Genomic ... 2019 - Global Version" report to their ... the area of molecular diagnostics and pharmacogenics hold ... world market that is moving out of the ...
(Date:5/5/2015)... , May 5, 2015 CytomX, a biotechnology ... today announced that Sean McCarthy , D. Phil., ... Antibody Day in New York ... McCarthy will present an overview of CytomX,s Probody pipeline, ... conjugate programs. About CytomX Therapeutics CytomX ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... As adjunctive therapy Keppra XR(TM) offers significant partial onset ... ... heritage, ATLANTA, Sept. 15 press release, regulated information:,UCB ... has,approved Keppra XR(TM) (levetiracetam extended-release tablets) for use as,an add-on ...
... Diagnostics, Inc. today,announced the appointment of Johan Skog, ... Dr. Skog will oversee the research program that,underlies ... can,identify cancer-specific genetic mutations., Dr. Skog is ... technology that has been licensed exclusively to the ...
... milestone payments and promotional investment totaling up to ... $385 million ... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today that it ... prolonged release,tablets) in Europe and other countries to the Menarini ...
Cached Biology Technology:Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 2CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 3CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 5